Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
77 hedge funds and large institutions have $247M invested in Orchard Therapeutics plc American Depositary Shares in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 10 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 16
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
7% more funds holding
Funds holding: 72 → 77 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less capital invested
Capital invested by funds: $265M → $247M (-$17.8M)
78% less call options, than puts
Call options by funds: $237K | Put options by funds: $1.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.64M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$2.55M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$1.68M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.18M |
| 5 |
Goldman Sachs
New York
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$11.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.8M |
| 3 |
CC
Casdin Capital
New York
|
-$7.69M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.19M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$2.78M |
ORTX Hedge Fund Activity: Q4 2020 in Review
77 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q4 2020, worth a combined $247M — down 6.7% from $265M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ORTX positions and 10 closed out — a net gain of 5 holders — while 32 added to existing stakes and 16 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $3.64M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $11.3M sold.
- 77 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q4 2020, up from 72 in Q3 2020.
- Funds reported $247M of Orchard Therapeutics plc American Depositary Shares stock for Q4 2020, down 6.7% quarter-over-quarter.
- 15 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q4 2020 and 10 closed out, a net change of +5 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q4 2020 was JP Morgan Chase, an estimated $3.64M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q4 2020 was Baillie Gifford & Co, an estimated $11.3M sold.
Based on aggregated 13F filings for Q4 2020.